Zydus Cadila gets USFDA nod for Colesevelam Hydrochloride tablets for lowering cholesterol

Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Colesevelam Hydrochloride tablets, in the strength of 625 mg, the company said in a BSE filing.

New Delhi: Drug firm Zydus Cadila on Wednesday said it has received final approval from the US health regulator to market generic cholesterol-lowering Colesevelam Hydrochloride tablets.

Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Colesevelam Hydrochloride tablets, in the strength of 625 mg, the company said in a BSE filing.

The product will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad, it added.

Read Also: Zydus announces positive results from EVIDENCES IV Phase 2 clinical trial of Saroglitazar Magnesium in NAFLD and NASH

The medication is used along with a proper diet and exercise to lower cholesterol level, the company said.

The group now has 273 approvals and has so far filed over 360 abbreviated new drug applications (ANDAs) since the commencement of its filing process, it added.

Read Also: Zydus receives final approval from USFDA for Clobetasol Propionate Lotion